Hematologic cancer survivorship management: Lymphoma

Maria Alma Rodriguez, Leslie Ballas, Kristin Simar

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lymphoid malignancies are a family of diverse cancers arising in the cells of the immune system. Lymphoid leukemia, lymphoma, and myeloma belong to this category of cancers. This chapter will focus on lymphomas and the late effects of treatment. Lymphomas are broadly categorized into Hodgkin lymphomas, which are uncommon, and non-Hodgkin lymphomas, which are the sixth most common malignancy in men and women. Incidence of non-Hodgkin lymphoma appears to be rising, although the reasons for this are unclear. Treatment for lymphoma has improved substantially over the past 50 years, resulting in a large population of long-term lymphoma survivors. Patients with lymphoma are treated principally with chemotherapy, immunotherapy, radiation, or stem cell transplantation. Surgery generally does not have a role in the treatment of these disorders except in rare cases. Different treatment modalities have different late side effects. In this chapter, we will summarize the most commonly known potential late effects of chemotherapeutic agents and radiation, the few situations in which surgery is used and its long-term effects, and recommended practice for surveillance of recurrence and late effects.

Original languageEnglish (US)
Title of host publicationAdvances in Cancer Survivorship Management
PublisherSpringer New York
Pages201-218
Number of pages18
ISBN (Electronic)9781493909865
ISBN (Print)9781493909858
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Hematologic cancer survivorship management: Lymphoma'. Together they form a unique fingerprint.

Cite this